Cumberland Pharmaceuticals Inc revenue
Cumberland Pharmaceuticals Inc's revenue was $44.5m in fiscal 2025, up 17.6% on the year before. Since fiscal 2009 ($43.5m) it has grown at a compound 0.1% a year. Over the last twelve months it was $39.9m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44 | 46 | 51 | 49 | 32 | 37 | 34 | 33 | 41 | 29 | 34 | 37 | 36 | 42 | 40 | 38 | 45 | 40 |
| Growth on the year before | — | +5.4% | +11.5% | −4.5% | −34.4% | +15.2% | −9.2% | −1.5% | +24.6% | −28.7% | +17.2% | +8.9% | −3.9% | +16.7% | −5.9% | −4.3% | +17.6% | — |
| Gross profit | — | — | — | — | — | — | — | 27 | 34 | 23 | 27 | 29 | 27 | 33 | 33 | 31 | 38 | — |
| Gross margin | — | — | — | — | — | — | — | 82.0% | 82.1% | 79.5% | 78.4% | 76.9% | 75.5% | 78.3% | 84.7% | 82.6% | 85.0% | — |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $40.4M | ▲ 10.6% |
| Product Sancuso | $11.9M | ▲ 32.2% |
| Product Kristalose | $10.5M | ▼ 31.2% |
| Product Vibativ | $9.5M | ▲ 32.5% |
| Product Caldolor | $4.7M | ▼ 6.0% |
| Manufactured Product Other | $4.1M | ▲ 210.1% |
| Product Other | $4.1M | ▲ 210.1% |
| Product Talicia | $3.3M | — |
| Product Acetadote | $508,169 | ▲ 174.4% |
| Product Redi Trex | $11,391 | ▼ 87.4% |
| Product Omeclamox Pak | -$10,436 | — |
| Product Vaprisol | -$18,346 | — |
These categories overlap or exclude eliminations, so shares aren't shown.
From Cumberland Pharmaceuticals Inc's 10-K filed March 9, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Cumberland Pharmaceuticals Inc | $39.9m | -5.2% | -0.6% |
| IM Cannabis Corp. | $39.2m | -0.7% | — |
| BGM Group Ltd. | $37.9m | 51.1% | — |
| Sunshine Biopharma Inc. | $35.3m | -2.7% | 34.5% |
| Biofrontera Inc. | $46.2m | 17.8% | 16.7% |
| Scilex Holding Co | $31.6m | -28.5% | -12.0% |
Compare with peers
- IM Cannabis Corp. revenue
- BGM Group Ltd. revenue
- Sunshine Biopharma Inc. revenue
- Biofrontera Inc. revenue
- Scilex Holding Co revenue
Head to head: CPIX vs IMCCBGM vs CPIXCPIX vs SBFMBFRI vs CPIX
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies